Snapshot biomarkers currently used to guide therapy selection, such PD-L1 expression and TMB, rely on analysis of tumor tissue obtained through invasive single-region biopsies, which may not sufficiently capture the clonal complexity of tumors, may be problematic in the event of low tumor purity sampling and, importantly, do not capture the evolving tumor under the selective pressure of immunotherapy. The gene discussed is CD274; the disease is neoplasm.